KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Receivables (2016 - 2025)

Gilead Sciences' Receivables history spans 17 years, with the latest figure at $5.5 billion for Q4 2025.

  • For Q4 2025, Receivables fell 0.96% year-over-year to $5.5 billion; the TTM value through Dec 2025 reached $5.5 billion, down 0.96%, while the annual FY2025 figure was $5.5 billion, 0.96% down from the prior year.
  • Receivables reached $5.5 billion in Q4 2025 per GILD's latest filing, down from $5.8 billion in the prior quarter.
  • In the past five years, Receivables ranged from a high of $5.8 billion in Q3 2025 to a low of $3.9 billion in Q1 2022.
  • Average Receivables over 5 years is $4.9 billion, with a median of $4.8 billion recorded in 2024.
  • Peak YoY movement for Receivables: increased 29.67% in 2021, then fell 18.32% in 2022.
  • A 5-year view of Receivables shows it stood at $4.7 billion in 2021, then increased by 6.02% to $4.9 billion in 2022, then increased by 13.42% to $5.6 billion in 2023, then dropped by 0.29% to $5.6 billion in 2024, then decreased by 0.96% to $5.5 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's Receivables are $5.5 billion (Q4 2025), $5.8 billion (Q3 2025), and $5.1 billion (Q2 2025).